Delving into the Latest Updates on oVV-ING4 with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms

Target

ING4

Mechanism

ING4 modulators(inhibitor of growth family member 4 modulators)

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Relapsing acute myeloid leukemia

Inactive Indication-

Originator Organization

Zhejiang Chinese Medical University

Active Organization

Zhejiang Chinese Medical University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

BACKGROUNDIn consideration of the drug resistance and side effects associated with cytarabine, one of the most effective drugs for the treatment of acute myeloid leukemia (AML), there is a need for safer and effective strategies.METHODSIn the present investigation, we fabricated a new oncolytic vaccinia virus (oVV-ING4), which expresses the inhibitor of growth family member 4 (ING4) and explored its antitumor activity individually and in combination with cytarabine in AML cells.RESULTSThe experiments confirmed that oVV can efficiently and specifically infect leukemia cells, and augment the ING4 gene expression. Flow cytometry and western blot demonstrated that oVV-ING4 enhances apoptosis and G2/M phase arrest in AML cells, and causes remarkable cancer cell death. In addition, the synergistic efficiency of oVV-ING4 and cytarabine was investigated in vitro and in vivo; the combination significantly inhibited the survival of leukemia cells in vitro and xenografted KG-1 AML tumor growth in vivo.CONCLUSIONIn brief, oVV-ING4 can increase the sensitivity of leukemia cells to cytarabine and induce cell apoptosis in vitro and in vivo. Thus, oVV-ING4 may be a promising therapeutic candidate for leukemia and in combination with cytarabine represents a potential antitumor therapy.

100 Deals associated with oVV-ING4

Login to view more data